- Todos Medical Initiates IRB-Waived Tollovid Market Research Study and Announces 50% Price Reduction Until May 30th, 2022
- Todos Medical to Present at the Emerging Growth Conference
- Todos Medical Appoints Philippe Goix as Chief Commercial Officer for Provista Diagnostics
- Todos Medical Reports 2nd Long COVID Case Study and Launches Website for Physicians and Pediatricians to Indicate Interest in Participating in Tollovid Long COVID Clinical Study
- Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid by LGC Group
- Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate of Free Sale with Daily and Acute Dosing on the Label
- Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants
- Update: Todos Medical Reports Fourth-Quarter and Full-Year 2021 Financial Results and Corporate Updates
- Todos Medical Reports Fourth-Quarter and Full-Year 2021 Financial Results and Corporate Updates
- Todos Medical Reports Case Study of Patient with Long COVID
More ▼
Key statistics
As of last trade, Todos Medical Ltd (TOMDF:QBB) traded at 0.0127, 14.93% above the 52 week low of 0.0111 set on May 16, 2022.
52-week range
Open | 0.0134 |
---|---|
High | 0.0135 |
Low | 0.0126 |
Bid | -- |
Offer | -- |
Previous close | 0.0134 |
Average volume | 2.18m |
---|---|
Shares outstanding | 1.19bn |
Free float | 968.04m |
P/E (TTM) | -- |
Market cap | 15.99m USD |
EPS (TTM) | -0.0388 USD |
Data delayed at least 15 minutes, as of Jun 28 2022 20:16 BST.
More ▼